# 2026年2月28日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 循环微RNA作为儿童癫痫的生物标志物：一项纵向队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41757388)
**期刊：** Epilepsia
**PMID：** 41757388
**DOI：** 10.1002/epi.70166

### 第一部分 原文与翻译

**英文原标题：** Circulating microRNAs as biomarkers in pediatric epilepsy: A longitudinal cohort study.

> **英文摘要：**
> OBJECTIVE: Epilepsy is the most common chronic neurological disorder in children, and approximately one third of patients develop drug-resistant seizures. Reliable biomarkers are needed to improve diagnosis, prognostic assessment, and treatment monitoring. This study evaluated four circulating microRNAs-miR-15a-5p, miR-106b-5p, miR-146a-5p, and miR-152-3p-as potential diagnostic and prognostic biomarkers in pediatric epilepsy. METHODS: A total of 122 pediatric patients with epilepsy and 29 age- and sex-matched healthy controls were prospectively enrolled at Bambino Gesù Children's Hospital (Rome) between 2022 and 2025. Clinical variables included epilepsy type, etiology, seizure frequency, electroencephalography, magnetic resonance imaging, and comorbidities. Serum miRNAs were measured by reverse transcription quantitative polymerase chain reaction and normalized using the 2 method, accounting for hemolysis. Nonparametric tests (Mann-Whitney, Kruskal-Wallis, Wilcoxon) were used for comparisons. Forty-three patients were reevaluated after ≥12 months to assess longitudinal expression. RESULTS: All four miRNAs were significantly upregulated in children with epilepsy compared to controls (p < .05). miR-146a-5p expression differed among etiological groups, being higher in structural compared with genetic or unknown etiologies (p = .014). Both miR-15a-5p and miR-106b-5p correlated with seizure frequency, showing greater expression in patients with monthly-to-daily seizures than in those with sporadic seizures or seizure-free patterns (p = .004 and p = .017). No association was found with antiseizure medications, intellectual disability, or psychiatric comorbidities. Longitudinal analysis showed a significant increase in miR-15a-5p and miR-106b-5p at follow-up (p < .01), independent of clinical outcome, whereas miR-146a-5p remained stable over time. These findings suggest that miR-15a-5p and miR-106b-5p reflect ongoing epileptic activity, whereas miR-146a-5p may relate to underlying pathophysiology rather than seizure dynamics. SIGNIFICANCE: Circulating miRNAs represent promising, minimally invasive biomarkers in pediatric epilepsy. miR-146a-5p may aid etiologic classification, whereas miR-15a-5p and miR-106b-5p could serve as dynamic indicators of disease burden and treatment response, supporting biomarker-driven precision approaches in epilepsy care.

> **中文摘要：**
> 目的：癫痫是儿童最常见的慢性神经系统疾病，约有三分之一的患者会发展为耐药性癫痫发作。需要可靠的生物标志物来改进诊断、预后评估和治疗监测。本研究评估了四种循环微RNA（miR-15a-5p、miR-106b-5p、miR-146a-5p和miR-152-3p）作为儿童癫痫潜在诊断和预后生物标志物的价值。方法：2022年至2025年间，在罗马耶稣圣婴儿童医院前瞻性招募了共122名癫痫患儿和29名年龄及性别匹配的健康对照者。临床变量包括癫痫类型、病因、发作频率、脑电图、磁共振成像和共病。通过逆转录定量聚合酶链反应测量血清miRNA，并使用2^-ΔΔCt方法进行归一化（考虑溶血因素）。使用非参数检验（Mann-Whitney、Kruskal-Wallis、Wilcoxon）进行比较。43名患者在12个月或更长时间后接受了重新评估，以评估纵向表达情况。结果：与对照组相比，癫痫患儿中所有四种miRNA均显著上调（p < .05）。miR-146a-5p的表达在不同病理组之间存在差异，结构性病因患者的表达高于遗传性或未知病因患者（p = .014）。miR-15a-5p和miR-106b-5p均与发作频率相关，在每月至每日发作的患者中表达高于散发性发作或无发作模式的患者（p = .004 和 p = .017）。未发现与抗癫痫药物、智力障碍或精神共病之间存在关联。纵向分析显示，随访时miR-15a-5p和miR-106b-5p显著增加（p < .01），且与临床结局无关，而miR-146a-5p随时间保持稳定。这些发现表明，miR-15a-5p和miR-106b-5p反映了持续的癫痫活动，而miR-146a-5p可能与潜在的病理生理学而非发作动态有关。意义：循环miRNA是儿童癫痫中具有前景的微创生物标志物。miR-146a-5p可能有助于病因分类，而miR-15a-5p和miR-106b-5p可作为疾病负担和治疗反应的动态指标，支持癫痫护理中生物标志物驱动的精准治疗方法。

### 第二部分 AI 大师评价

本研究通过前瞻性纵向队列设计，深入探讨了特定循环miRNA在儿童癫痫临床管理中的双重价值。研究发现miR-146a-5p具有区分结构性与非结构性病因的潜力，而miR-15a-5p和miR-106b-5p则表现出与发作频率及疾病负荷的正相关性。创新点在于揭示了不同miRNA在反映基础病理与实时癫痫活动上的功能异质性，为实现癫痫的分子亚型分类与动态病情监测提供了重要的微创证据。局限性可能在于纵向样本量相对较小，仍需多中心更大规模研究验证其在预测耐药性发展中的长期临床效用。

---

## 2. 原发运动皮层受累及其与脑转移瘤患者癫痫发作风险的相关性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747204)
**期刊：** Neurology
**PMID：** 41747204
**DOI：** 10.1212/WNL.0000000000214714

### 第一部分 原文与翻译

**英文原标题：** Primary Motor Cortex Involvement and Its Association With Seizure Risk in Patients With Brain Metastases.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Seizures are common in patients with brain metastases (BMs), causing significant morbidity and reduced quality of life. The relationship between BM location and seizure risk remains unclear. Nononcologic literature suggests that primary motor cortex disruption may predispose to seizures. This study evaluated whether BM in primary motor cortex display increased seizure risk relative to BM in other locations. METHODS: In this retrospective cohort study, patients with radiographic evidence of BM managed at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2003 and 2022, and maintained in a database, were included. Abstracted covariables spanned demographic (age, sex, and race), clinical (comorbidities and performance status), oncologic (cancer type, extracranial/intracranial disease extent, and prior systemic therapy), radiotherapeutic/neurosurgical (employment and type of radiation, presence of preceding brain-directed surgery), and outcome/seizure-related (presence, timing, and nature of seizures) domains. The exposure variable was BM in the primary motor cortex, and the outcome measure was seizures on a per-patient level. The effect of primary motor cortex involvement on seizure risk, at diagnosis and thereafter, was evaluated using univariable/multivariable logistic, and Fine and Gray competing risks regression, respectively. To limit confounding by lesion number, analyses were repeated in patients with a single BM at diagnosis (n = 1,174). RESULTS: Among 3,043 patients with (n = 570, 18.7%) vs without (n = 2,473, 81.3%) BM in primary motor cortex, the mean age was 60 vs 61 years, and 61% vs 62% of patients were female, respectively. Primary motor cortex involvement was associated with increased seizure risk at diagnosis (24.4% vs 10.3%, odds ratio 2.87, 95% CI 2.23-3.98, < 0.001) and after initial diagnosis (hazard ratio [HR] 1.95, 95% CI 1.56-2.43, < 0.001). Of 1,446 patients who developed additional BM after initial intracranial oncologic involvement, those with disease involving primary motor cortex were more likely to develop seizures thereafter (HR 2.11, 95% CI 1.56-2.86, < 0.001). DISCUSSION: Patients with BM in the primary motor cortex may display increased seizure risk. As this study was retrospective, routine use of antiseizure medications in patients with BM in primary motor cortex in the off-trial setting is not recommended. However, dedicated trials evaluating prophylactic antiseizure medications in this population may be warranted.

> **中文摘要：**
> 背景与目的：癫痫在脑转移瘤（BM）患者中很常见，会导致显著的发病率并降低生活质量。目前脑转移瘤位置与癫痫风险之间的关系尚不清楚。非肿瘤学文献提示，原发运动皮层受损可能使患者产生癫痫倾向。本研究评估了与位于其他部位的脑转移瘤相比，位于原发运动皮层的脑转移瘤是否表现出更高的癫痫风险。方法：在这项回顾性队列研究中，纳入了2003年至2022年间在布莱根妇女医院/丹娜-法伯癌症研究所接受治疗，且影像学证据证实为脑转移瘤并记录在数据库中的患者。提取的协变量涵盖人口统计学（年龄、性别和种族）、临床（合并症和体能状态）、肿瘤学（癌症类型、颅外/颅内疾病范围和既往全身治疗）、放射治疗/神经外科（放疗的实施和类型、是否存在先前的脑部定向手术）以及结局/癫痫相关（癫痫的存在、时间和性质）领域。暴露变量为原发运动皮层存在脑转移瘤，结局指标为患者个体层面的癫痫发作。分别使用单变量/多变量逻辑回归以及 Fine and Gray 竞争风险回归评估原发运动皮层受累对诊断时及诊断后癫痫风险的影响。为了限制病灶数量带来的混杂影响，在诊断时仅患有单个脑转移瘤的患者（n = 1,174）中重复了分析。结果：在3,043名患者中，原发运动皮层受累者为570人（18.7%），未受累者为2,473人（81.3%），两组平均年龄分别为60岁和61岁，女性比例分别为61%和62%。原发运动皮层受累与诊断时癫痫风险增加相关（24.4% vs 10.3%，比值比 2.87，95% CI 2.23-3.98，p < 0.001），且与初始诊断后的风险增加相关（风险比 [HR] 1.95，95% CI 1.56-2.43，p < 0.001）。在1,446名初始颅内肿瘤受累后出现额外脑转移瘤的患者中，疾病涉及原发运动皮层的患者随后发生癫痫的可能性更高（HR 2.11，95% CI 1.56-2.86，p < 0.001）。讨论：原发运动皮层受累的脑转移瘤患者可能表现出更高的癫痫风险。由于本研究是回顾性的，不建议在临床试验之外对原发运动皮层受累的脑转移瘤患者常规使用抗癫痫药物。然而，可能有必要在该人群中开展评估预防性抗癫痫药物的专门试验。

### 第二部分 AI 大师评价

本研究是一项高质量的大规模回顾性队列研究，系统探讨了脑转移瘤解剖位置与癫痫风险的关联。通过对三千余例患者的长期随访数据分析，研究明确指出原发运动皮层受累是脑转移瘤患者癫痫发作的强效且独立的风险因素，其风险提升约2至3倍。该发现不仅在统计学上具有高度显著性，且在控制了病灶数量等混杂因素后依然稳健。尽管受限于回顾性研究性质，目前尚不能据此直接更改常规预防性用药指南，但它为癫痫高风险患者的精准识别提供了明确的神经解剖学标志，并为未来开展针对性预防治疗的随机对照试验奠定了坚实的实证基础。

---

速递结束，祝您工作愉快！